The European Commission (EC) has approved the marketing authorisation of lutetium (¹⁷⁷Lu) oxodotreotide (Lutathera) for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.

Read more here: http://ecancer.org/news/12480-european-approval-of-lutetium-oxodotreotide-for-gastroenteropancreatic-neuroendocrine–gep-net–tumours.php

We have to be next!!